Are peptides legal? What US law actually says in 2026

“Peptide” is a chemistry word, not a legal category. US law does not regulate peptides as a class. It regulates drugs, and whether a given peptide product is legal depends on three questions:

1. Has FDA approved it as a drug?
2. If not, is a licensed pharmacy compounding it under the rules?
3. If neither, what is the seller saying it is for?

This page walks through each, with links to the records. It is reporting, not legal advice.

What are the legal pathways for peptides?

Bucket	Examples	Legal status (US, Oct 2026)
FDA-approved peptide drugs	Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta), bremelanotide (Vyleesi), insulin, oxytocin	Legal with a prescription, dispensed by a pharmacy
Compounded peptides	A pharmacy-prepared peptide for a named patient	Legal only if the pharmacy meets section 503A or 503B conditions, including where the bulk ingredient comes from
“Research use only” peptides	BPC-157, TB-500, retatrutide, CJC-1295 and others sold online in vials	Not approved for human use. FDA treats them as unapproved new drugs when the seller markets them for people
Cosmetic / topical peptides	GHK-Cu or “copper peptide” skin creams	Regulated as cosmetics if marketed only for appearance. Drug claims change that
Imported peptides	Vials ordered from overseas sellers	Subject to FDA review at the border. Personal importation is enforcement discretion, not a right, and unapproved injectables can be detained and refused (explainer)
Peptides in sport	BPC-157, TB-500, ipamorelin, GHRPs	Separate from the law: WADA prohibits BPC-157 (S0) and growth-hormone secretagogues and thymosin beta-4 derivatives (S2) (explainer)

Bucket 1: Are FDA-approved peptide drugs legal?

An FDA-approved peptide drug has been through a new drug application showing it is safe and effective for a specific use. It is legal to prescribe and dispense. A doctor may also prescribe it off-label. A product with the same molecule that is not the approved product is a different legal object, even if the chemical name matches. FDA’s letters to online sellers make this point repeatedly. In February 2025, for example, FDA told USApeptide.com that although “there are FDA-approved versions of semaglutide,” there were “no approved drug applications” for the semaglutide that site sold (letter).

Bucket 2: When are compounded peptides legal?

Compounding is a pharmacist mixing or altering ingredients to make a drug for a patient. Federal law gives two lanes:

• Section 503A, for state-licensed pharmacies and physicians compounding for identified patients on a prescription.
• Section 503B, for FDA-registered “outsourcing facilities” that follow current good manufacturing practice.

Under 503A, a pharmacy can compound from a bulk drug substance only if the substance (a) has a USP or NF monograph, (b) is a component of an FDA-approved drug, or (c) is on FDA’s 503A bulks list, which is set by rulemaking. The bulk substance must also come from an FDA-registered establishment with a valid certificate of analysis. Full detail is in 503A vs 503B.

While the bulks list is being built, FDA sorts nominated substances into interim categories. Category 1 gets enforcement discretion. Category 2 is for substances where FDA “has identified significant safety risks.” In 2023 FDA put many popular peptides in Category 2, including BPC-157, TB-500, CJC-1295, ipamorelin and others. That is the step people often call the “FDA peptide ban.” See Category 2 peptides.

What changed in 2026

• April 15: FDA said 12 peptides would leave Category 2 because the nominations had been withdrawn. That did not add them to the bulks list or Category 1 (report).
• July 23-24: FDA’s advisory committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for the bulks list, against FDA staff advice. The vote is advisory (report).
• October 14: An “Interim Access Policy for Compounding Using Certain Peptides” reached OMB review. It is not final and its text is not public (report).

So as of October 19, 2026, no research peptide that was in Category 2 has a settled lawful 503A pathway. That may change soon, and we will update this page when it does.

Bucket 3: Are “research use only” peptides legal?

This is where most of the search interest, and most of the enforcement, sits.

The label is not the test

A product is a drug if it is intended to treat or prevent disease or to affect the structure or function of the body (FD&C Act section 201(g)(1)). FDA decides intent from the seller’s own labeling, advertising and statements, under 21 CFR 201.128. A “not for human consumption” sticker is one piece of evidence. Product pages describing weight-loss trials, social media posts and dosing charts are others.

FDA’s warning letters show how it weighs that evidence. In the August 24, 2026 letter to Peptide Partners, FDA quoted product-page text about semaglutide and brain cells and retatrutide’s “powerful effects on weight loss.” It concluded that “despite statements on your product labeling marketing your products ‘for research use only’… your products are intended to be drugs for human use.” It also treated the company’s bacteriostatic water as a drug, because selling it alongside the peptides provided “the means to prepare an injectable drug for human administration” (letter). More in what ‘research use only’ means.

What happens to sellers

• Warning letters. These are the most common action, and the tracker logs each one. A letter is a formal notice, not a court judgment.
• Criminal cases. In July 2026 the owner of Paradigm Peptides was sentenced to 70 months after pleading guilty to selling unapproved drugs and illegal importation. He admitted the products were sold for human consumption (report). In April 2026 a Utah physician was indicted on misbranding charges over relabeled, China-sourced peptides. He is presumed innocent (report).
• Market exits. Science.bio (January 2026) and Peptide Sciences (March 2026) closed voluntarily without giving public reasons (status logs).

What about buyers?

The FD&C Act’s main prohibitions target introducing drugs into interstate commerce, which is what sellers do. Most research peptides, including BPC-157, TB-500, CJC-1295 and the GLP-1 analogs, are not listed in the federal Controlled Substances Act schedules. So possession alone is generally not a federal drug crime. That is the narrow answer to “is it illegal to buy.” It does not mean the product is safe, tested or lawful to sell to you. Separately:

• Imports can be detained or refused. FDA’s personal-importation policy is discretionary and does not cover injectable unapproved drugs as a right (importing explainer).
• State law varies, and some states regulate specific substances more tightly.
• Licensed professionals face licensing-board risk if they dispense unapproved products to patients.

Bucket 4: What about peptides in cosmetics?

Topical “copper peptide” (GHK-Cu) serums are sold as cosmetics. They stay cosmetics only as long as the marketing is about appearance. A claim to heal wounds or treat a condition makes the product a drug. Injectable GHK-Cu is a different matter: it appears on FDA’s Category 2 page in the “nominated but withdrawn” table, and it is not a cosmetic.

Are peptides allowed in sport?

Anti-doping rules apply on top of the law. WADA’s 2026 Prohibited List names BPC-157 under S0 (non-approved substances). Under S2 it covers growth hormone releasing factors and secretagogues, GHRPs such as ipamorelin and GHRP-2/-6, and thymosin beta-4 derivatives such as TB-500. See peptides in sport.

Does it depend on your state?

Only at the edges. Federal law decides whether a peptide is approved, compoundable or an unapproved new drug, and that answer is the same in every state. States decide who may prescribe, compound and dispense. As of October 19, 2026, the only peptide-specific state statute we have verified is Louisiana’s Act 374, effective August 1, 2026, which stops licensing boards from blocking prescribers and pharmacists who use federally compliant 503A or 503B compounding. Two Florida compounding bills died in committee in March 2026. Our state peptide laws page lists only states we can tie to a primary record, and FDA status by peptide shows the federal position for 25 peptides in one table.

How can you keep up with changes?

The legal picture moved four times in 2026, so check dates on anything you read, including this page. Our tracker logs each dated event with links to the record, and the CSV is free to reuse.